Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:12:42.230Z.
Consensus retrieved: 2026-10-06T12:56:17.189Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:12:42.230Z.
Quote observation: 2026-10-06T15:10:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b6dd554127bde3e2857ddd2c1d40451f36e78030673a0e1a1dc90bdbe20c6bc6
Forward PE Ratio (N/A) = Dated Quote Price ($106.19) / Consensus Forward EPS ($-0.20)
FORWARD PE RATIO
N/A
iRhythm Technologies, Inc.
Market Cap
$3.49B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| iRhythm Technologies, Inc. (IRTC) | $3.49B | N/A |
| CareDx, Inc (CDNA)vs › | $3.45B | 55.74 |
| Celcuity Inc. (CELC)vs › | $3.53B | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.54B | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.43B | 32.52 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.34B | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.10B | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.08B | 49.60 |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.08B | N/A |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.07B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $106.19, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.20 | $-0.22 – $-0.18 | 7 | n/m |
| 2027-12-31 | $1.16 | $0.90 – $1.59 | 7 | 91.4x |
| 2028-12-31 | $2.39 | $2.15 – $2.61 | 5 | 44.4x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
